New Study Validates NephroCheck® Test For Risk Of Acute Kidney Injury

New Study Validates NephroCheck® TestNew Study Validates NephroCheck® Test For Risk Of Acute Kidney Injury PR Newswire SAN DIEGO, March 3, 2014 A multi-center s t u d y published online in the American Journal of Respiratory and Critical Care Medicine (AJRCCM) validates the performance of the CE- ®marked NephroCheck Test, which assesses a critically ill patient's risk of developing acute kidney injury (AKI). ®The NephroCheck Test, developed by Astute Medical, Inc., utilizes fluorescence immunoassay technology to detect and measure two biomarkers of AKI, tissue inhibitor of metalloproteinase 2 (TIMP-2) and insulin-like growth factor binding protein 7(IGFBP-7) in human urine. The release of TIMP-2 and IGFBP-7 by kidney cells acts as a biological alarm signaling that the cells are acutely stressed and the kidney is at risk for AKI, which can cause permanent damage and loss of function. The recently published Kidney Disease Improving Global Outcomes (KDIGO) Guideline for AKI recommends prompt evaluation of patients along with the implementation of kidney-sparing interventions for patients determined to be at risk and thus vulnerable to permanent damage from unchecked AKI. "This first-of-its-kind study utilized clinical adjudication, the most rigorous standard, to prospectively validate two biomarkers for risk assessment of AKI," said first author Dr. Azra Bihorac of the University of Florida.